Found: 11
Select item for more details and to access through your institution.
Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 397, doi. 10.1007/s00280-023-04630-8
- By:
- Publication type:
- Article
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 411, doi. 10.1007/s00280-023-04623-7
- By:
- Publication type:
- Article
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 427, doi. 10.1007/s00280-023-04624-6
- By:
- Publication type:
- Article
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 439, doi. 10.1007/s00280-023-04635-3
- By:
- Publication type:
- Article
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 455, doi. 10.1007/s00280-023-04622-8
- By:
- Publication type:
- Article
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 471, doi. 10.1007/s00280-023-04633-5
- By:
- Publication type:
- Article
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 481, doi. 10.1007/s00280-023-04638-0
- By:
- Publication type:
- Article
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 497, doi. 10.1007/s00280-024-04641-z
- By:
- Publication type:
- Article
Pharmacology and pharmacokinetics of tazemetostat.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 5, p. 509, doi. 10.1007/s00280-024-04658-4
- By:
- Publication type:
- Article
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice